O
Olivier Molinier
Researcher at University of Montpellier
Publications - 124
Citations - 11257
Olivier Molinier is an academic researcher from University of Montpellier. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 26, co-authored 107 publications receiving 9574 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo,Tudor Ciuleanu,Lilia V. Stelmakh,Saulius Cicenas,Aleksandra Szczesna,E. Juhasz,Emilio Esteban,Olivier Molinier,Wolfram Brugger,Ivan Melezínek,Gaelle Klingelschmitt,Barbara Klughammer,Giuseppe Giaccone +12 more
TL;DR: Maintenance therapy with erlotinib for patients with NSCLC is well tolerated and significantly prolongs PFS compared with placebo, and PFS in patients whose tumours had EGFR protein overexpression, as determined by immunohistochemistry.
Journal ArticleDOI
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gérard Zalcman,Gérard Zalcman,Julien Mazieres,Jacques Margery,Laurent Greillier,Clarisse Audigier-Valette,Denis Moro-Sibilot,Olivier Molinier,Romain Corre,Isabelle Monnet,Valérie Gounant,Frédéric Rivière,H. Janicot,Radj Gervais,Chrystele Locher,Bernard Milleron,Quan Tran,Marie-Paule Lebitasy,Franck Morin,Christian Creveuil,Jean-Jacques Parienti,Arnaud Scherpereel +21 more
TL;DR: Addition of bevacizumab to pemetrexed plus cisplatin significantly improved OS in malignant pleural mesothelioma at the cost of expected manageable toxic effects, therefore it should be considered as a suitable treatment for the disease.
Journal ArticleDOI
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Michael Thomas,Jean-Louis Pujol,Paolo Bidoli,Olivier Molinier,Tarini Prasad Sahoo,E. Laack,Martin Reck,Jesus Corral,Symantha Melemed,William J. John,Nadia Chouaki,Annamaria Zimmermann,Carla Visseren-Grul,Cesare Gridelli +16 more
TL;DR: There was a significant reduction in the risk of disease progression over the placebo group, and the primary endpoint was progression-free survival in the intention-to-treat population.
Journal ArticleDOI
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Mike Thomas,Jean-Louis Pujol,Paolo Bidoli,Olivier Molinier,Tarini Prasad Sahoo,Eckart Laack,Martin Reck,Jesus Corral,Symantha Melemed,William J. John,Nadia Chouaki,Annamaria Zimmermann,Carla Visseren-Grul,Cesare Gridelli +16 more
TL;DR: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexing-cisplatin induction therapy.